

Jennifer E Miller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4115214/publications.pdf>

Version: 2024-02-01

48
papers

965
citations

430754

18
h-index

477173

29
g-index

51
all docs

51
docs citations

51
times ranked

1129
citing authors

#	ARTICLE	IF	CITATIONS
1	Diversity in clinical research: public health and social justice imperatives. <i>Journal of Medical Ethics</i> , 2023, 49, 200-203.	1.0	15
2	Ethical considerations in international clinical trial site selection. <i>BMJ Global Health</i> , 2022, 7, e008012.	2.0	4
3	Just allocation of COVID-19 vaccines. <i>BMJ Global Health</i> , 2021, 6, e004812.	2.0	28
4	Equitable Access to Research Benefits: Considerations for COVID-19 Vaccine Development and Clinical Trial Crossover. <i>American Journal of Bioethics</i> , 2021, 21, 86-88.	0.5	3
5	COVID-19 vaccine research and the trouble with clinical equipoise. <i>Lancet, The</i> , 2021, 397, 576.	6.3	10
6	Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics. <i>JAMA Network Open</i> , 2021, 4, e217063.	2.8	22
7	Direct-to-consumer personal genomic tests need better regulation. <i>Nature Medicine</i> , 2021, 27, 940-943.	15.2	7
8	Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs. <i>JAMA Network Open</i> , 2021, 4, e217075.	2.8	24
9	2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report. <i>Circulation</i> , 2021, 143, e1035-e1087.	1.6	13
10	2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3079-3133.	1.2	12
11	Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis. <i>BMJ Open</i> , 2021, 11, e053248.	0.8	8
12	Implementation of 21st Century Cures Act Expanded Access Policies Requirements. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1579-1584.	2.3	3
13	Blood, Sweat, and Fears: A Novel Mutation Associated With Anaphylaxis and Nonresponse in a Patient With Afibrinogenemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e260-e263.	0.3	1
14	Managing acute agitation and aggression in the world of drug shortages. <i>Mental Health Clinician</i> , 2021, 11, 334-346.	0.5	5
15	Access to COVID-19 Vaccines in High-, Middle-, and Low-Income Countries Hosting Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e2134233.	2.8	24
16	Managing conflicts of interest in pharmacy and therapeutics committees: A proposal for multicentre formulary development. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 249-255.	0.7	2
17	Skin testing with different food formulations in pediatric patients with eosinophilic esophagitis. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 329-332.	1.1	0
18	Racial Privilege and Medical Student Awards: Addressing Racial Disparities in Alpha Omega Alpha Honor Society Membership. <i>Journal of General Internal Medicine</i> , 2020, 35, 3348-3351.	1.3	20

#	ARTICLE	IF	CITATIONS
19	Ethical implications of poor comparative effectiveness evidence: obligations in industry-research partnerships. <i>Lancet, The</i> , 2020, 395, 926-928.	6.3	6
20	Quality of life in food allergic children. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 379-384.	0.5	32
21	Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices. <i>BMJ: British Medical Journal</i> , 2019, 366, l4217.	2.4	40
22	Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis. <i>BMC Medicine</i> , 2019, 17, 117.	2.3	14
23	IgE-Mediated Food Allergy. <i>Clinical Reviews in Allergy and Immunology</i> , 2019, 57, 244-260.	2.9	190
24	Therapeutic Orphans. <i>The National Catholic Bioethics Quarterly</i> , 2019, 19, 27-35.	0.1	0
25	Delays in the Publication of Important Clinical Trial Findings in Oncology. <i>JAMA Oncology</i> , 2018, 4, e180264.	3.4	26
26	Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs. <i>JAMA Network Open</i> , 2018, 1, e180283.	2.8	23
27	Adherence to the International Committee of Medical Journal Editors's (ICMJE) prospective registration policy and implications for outcome integrity: a cross-sectional analysis of trials published in high-impact specialty society journals. <i>Trials</i> , 2018, 19, 448.	0.7	49
28	Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study. <i>Trials</i> , 2018, 19, 581.	0.7	24
29	Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies. <i>BMJ Open</i> , 2017, 7, e017917.	0.8	46
30	Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. <i>Trials</i> , 2017, 18, 333.	0.7	43
31	Characterizing expanded access and compassionate use programs for experimental drugs. <i>BMC Research Notes</i> , 2017, 10, 350.	0.6	20
32	Incorporating ethical principles into clinical research protocols: a tool for protocol writers and ethics committees. <i>Journal of Medical Ethics</i> , 2016, 42, 229-234.	1.0	9
33	Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012. <i>BMJ Open</i> , 2015, 5, e009758.	0.8	71
34	Developing Drugs Differently Good Pharma: The Public-Health Model Of The Mario Negri Institute By Light Donald W. Mauro Antonio F. London (UK) : Palgrave Macmillan , 2015 300Âpp., \$95.00. <i>Health Affairs</i> , 2015, 34, 2202-2202.	2.5	0
35	Urine testing for antipsychotics: a pilot trial for a method to determine detection levels. <i>Human Psychopharmacology</i> , 2015, 30, 350-355.	0.7	4
36	Gatekeepers for pragmatic clinical trials. <i>Clinical Trials</i> , 2015, 12, 442-448.	0.7	32

#	ARTICLE	IF	CITATIONS
37	The ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trials. <i>Clinical Trials</i> , 2015, 12, 503-510.	0.7	59
38	Bioethical accreditation or rating needed to restore trust in pharma. <i>Nature Medicine</i> , 2013, 19, 261-261.	15.2	6
39	From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy Practices through Accreditation, Certification, and Rating. <i>Journal of Law, Medicine and Ethics</i> , 2013, 41, 601-610.	0.4	11
40	How a Clinical Trial Registry Became a Symbol of Misinformation. <i>Hastings Center Report</i> , 2013, 43, 11-12.	0.7	3
41	Irreligious Bioethics, Nonsense on Stilts?. <i>American Journal of Bioethics</i> , 2012, 12, 15-17.	0.5	3
42	BioCEP. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2012, 21, 409-416.	0.5	2
43	Ethical issues in pediatric emergency mass critical care. <i>Pediatric Critical Care Medicine</i> , 2011, 12, S163-S168.	0.2	37
44	Editorial Commentsâ€”Pandemic Influenza Triage in the Clinical Setting. <i>Prehospital and Disaster Medicine</i> , 2010, 25, 105-106.	0.7	0
45	Impact of the National Institutes of Health Consensus Development Program on stimulating National Institutes of Healthâ€”funded research, 1998 to 2001. <i>International Journal of Technology Assessment in Health Care</i> , 2007, 23, 343-348.	0.2	5
46	Tenâ€”year experience of unrelated bone marrow donor transplants in children with malignant and nonâ€”malignant conditions. <i>Pediatric Transplantation</i> , 1999, 3, 49-59.	0.5	2
47	Aspects of Hausa intonation, 2: continuous text. <i>Journal of the International Phonetic Association</i> , 1982, 12, 78-93.	0.6	3
48	Aspects of Hausa intonation, 1: utterances in isolation. <i>Journal of the International Phonetic Association</i> , 1980, 10, 45-63.	0.6	4